For US Residents Only View Healthcare Professional Site >
Important Safety Information Full Prescribing Information View​ HCP Site

Find a Location

To find the nearest imaging center that offers Illuccix®, please enter your zip code or address. Results will show 5 of the closest locations within a 100 mile radius.

Telix Pharmaceuticals encourages patients to reach out to their physician or a member of their care team. Telix Pharmaceuticals offers this “Site Locator” directory as a resource to help patients find an Illuccix dosing location that uses PSMA PET with Illuccix in a specific geographical area.

Please be advised: any communication outside this website is not covered by our Privacy Policy or Terms of Use. This listing is not an endorsement of the site. This listing is not a guarantee that the site has Illuccix or that Illuccix is appropriate for any specific patient. Not all Illuccix dosing locations are displayed. Facilities that have used Illuccix have the option of not being listed on this locator. Telix Pharmaceuticals does not warrant, whether expressed or implied, the accuracy, completeness, or feasibility of the information contained in the “Site Locator” directory. In no event shall Telix Pharmaceuticals be liable to you or anyone else for any actions taken by you in reliance on the information contained in the “Site Locator” directory. Telix Pharmaceuticals does not make any recommendations, referrals, or endorsements regarding specific imaging site locations with whom patients may seek treatment, nor does this site serve as a tool for verification of specific credentials, qualifications, or abilities. You assume full responsibility for your communications and interactions made with any location you choose to contact from the use of this “Site Locator” directory. Telix Pharmaceuticals is not responsible for the medical care or advice given by any site you choose to contact. By using the search field above, you agree to and accept the above terms. This free service provides a list of sites that may be qualified to provide Illuccix imaging. These sites do not pay a fee to be listed in the Illuccix Imaging Site Locator (“Locator”), and their participation does not impose any requirements on the manner in which they treat or provide services to patients. Participating sites are listed based on the geographical search information entered and whether the site has used Illuccix in the past. Some of the participating sites may have other financial relationships with Telix Pharmaceuticals as recipients of research grants or other similar payments. Sites may request to be removed from the Locator by clicking here. In addition, Telix Pharmaceuticals retains the right to remove sites from the Locator in its discretion.

Illuccix is widely available across the US, prepared and delivered from over 200 facilities

Approved Uses

ILLUCCIX® (kit for the preparation of gallium Ga-68 gozetotide, for injection) is a prescription radioactive diagnostic agent that is prepared by a healthcare provider, and, then, injected. It is used with a medical imaging procedure called Positron Emission Tomography (PET) of lesions identified as prostate-specific membrane antigen (PSMA) positive. ILLUCCIX is used in men with prostate cancer whose cancer may have spread to other parts of the body and may need initial therapy or whose cancer may have come back, based on elevated serum prostate-specific antigen (PSA) levels. ILLUCCIX is also approved to help your healthcare provider determine whether you are appropriate for a certain treatment that is a PSMA-directed therapy.

Important Safety Information

There is a risk your PET scan image with ILLUCCIX may be misinterpreted. A negative image does not rule out presence of prostate cancer, and a positive image does not confirm presence of prostate cancer. The ILLUCCIX PET scan may be affected by other factors, like the presence of other tissue types, PSMA levels and site of disease. Your healthcare provider will consider other information to confirm prostate cancer and determine treatment.

ILLUCCIX involves exposure to small amounts of radioactivity, and long-term cumulative radiation exposure is associated with increased risk for cancer. Your healthcare provider will use safe handling techniques to minimize radiation exposure.

Approved Uses

ILLUCCIX® (kit for the preparation of gallium Ga-68 gozetotide, for injection) is a prescription radioactive diagnostic agent that is prepared by a healthcare provider, and, then, injected. It is used with a medical imaging procedure called Positron Emission Tomography (PET) of lesions identified as prostate-specific membrane antigen (PSMA) positive. ILLUCCIX is used in men with prostate cancer whose cancer may have spread to other parts of the body and may need initial therapy or whose cancer may have come back, based on elevated serum prostate-specific antigen (PSA) levels. ILLUCCIX is also approved to help your healthcare provider determine whether you are appropriate for a certain treatment that is a PSMA-directed therapy.

Important Safety Information

  • There is a risk your PET scan image with ILLUCCIX may be misinterpreted. A negative image does not rule out presence of prostate cancer, and a positive image does not confirm presence of prostate cancer. The ILLUCCIX PET scan may be affected by other factors, like the presence of other tissue types, PSMA levels and site of disease. Your healthcare provider will consider other information to confirm prostate cancer and determine treatment.
  • ILLUCCIX involves exposure to small amounts of radioactivity, and long-term cumulative radiation exposure is associated with increased risk for cancer. Your healthcare provider will use safe handling techniques to minimize radiation exposure.
  • You should drink water to hydrate before the scan and urinate immediately before the procedure and as often as possible during the first hours after the procedure to help reduce radioactivity exposure.
  • The most common side effects of ILLUCCIX in clinical trials were fatigue, nausea, diarrhea, constipation, vomiting, and dizziness. These adverse reactions each typically occurred in ≤1.2% of patients in clinical trials.

The full Prescribing Information is available at www.ILLUCCIX.com. 

You are encouraged to report negative side effects to Telix Pharmaceuticals (US) at 1-844-455-8638 (pharmacovigilance@telixpharma.com) or to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Privacy Policy Terms of Use Contact Us About Telix

Illuccix® is a registered trademark of Telix Pharmaceuticals (US) Inc.
© 2024 Telix Pharmaceuticals (US) Inc. All rights reserved.

US-2100028v3 02/2024

Logo for Telix Pharmaceuticals
Logo for Telix Pharmaceuticals